Drug Discovery

Mallinckrodt to divest BioVectra for £202m

UK-based biopharmaceutical company Mallinckrodt has agreed to sell its wholly-owned subsidiary BioVectra to an affiliate of H.I.G. Capital for around $250m (£202m).

Veralox Therapeutics raises $5.4m in seed funding co-led by JDRF T1D Fund and Sanofi Ventures

Veralox Therapeutics, a preclinical stage company focused on accelerating the development of first-in-class therapeutics for unmet medical needs, has raised a $5.4 million seed funding round.

Sumitomo Dainippon, Roivant to create £2.4bn biopharma alliance

Japan-based Sumitomo Dainippon Pharma is set to take ownership of the stakes held by Roivant Sciences across five biopharma companies (Vants) in a deal worth $3bn (£2.43bn).

Maruho and X-Chem announce drug discovery collaboration

X-Chem has announced today a drug discovery partnership with Maruho to discover lead compounds for novel and challenging targets with applications for human diseases.

Boehringer Ingelheim signs £574m deal for Lupin’s MEK inhibitor compound

Boehringer Ingelheim has signed a licensing, development and commercialisation deal worth more than $700m (£573.85m) with Indian pharma company Lupin for the latter’s MEK inhibitor compound LNP3794.

Insilico Medicine develops AI-based drug discovery platform

US biotech company Insilico Medicine has developed a new artificial intelligence (AI) system for drug discovery, known as GENTRL.

Vertex to acquire US biotech firm Semma Therapeutics for £785m

Vertex Pharmaceuticals has agreed to acquire US-based biotech company Semma Therapeutics for $950m (£784.66m) in an all-cash deal with an aim to develop curative cell-based treatments for type 1 diabetes.

HiFiBiO Therapeutics closes £55m Series C financing

HiFiBiO Therapeutics, a US biotherapeutics company, which has developed a single-cell analytics platform for extensive immune profiling, has completed a $67m (£54.86m) Series C financing round.

Immatics, Celgene sign £1.3bn deal to develop cancer immunotherapies

Immatics Biotechnologies and Celgene have signed a collaboration and option deal worth up to $1.59bn (£1.3bn) to develop novel adoptive cell therapies against multiple cancers.